Bio Solution

At a glance

Bio Solution filed 24 disclosures in the last 12 months.

Revenue for 2025 was ₩15.2B, up 17.9% on 2024. It made an operating loss of ₩4.3B. Debt was 114% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩8.5B and operating loss of ₩1.8B.

The 2025 annual report lists 100 employees with an average tenure of 5.2 years and average pay of ₩57.2M, #1106 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩137M each on average. It paid no cash dividend for 2025. 장송선 and related parties held 19.30% at year end.

From the 2025 annual report

Staff: 100 (54 men, 46 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩5.7B. Directors and auditors: 6, paid ₩824M in total.

No cash dividend was paid for 2025.

Largest shareholder

장송선 holds 17.60%; with 3 related parties the group holds 19.30% of common shares at year end (from 20.11% at the start of the year).

Auditor: 회계법인 리안 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary